The name says it all: TYme ZAving VANcomycin.
With TYZAVAN™, you can:
Minimizes Medication Errors
Set up and start infusion1
Faster Administration
No compounding, thawing, or
activation required1
Standardize your
vancomycin protocol.
Achieve faster time to
antibiotic therapy.1
Ensure compliance with USP
<797> and cGMP Manufacturing.
Reduce pharmacy
workload.
Reduced Staff Workload
Seven ready-to-use strengths1
(500mg, 750mg, 1g, 1.25g, 1.5g, 1.75g, 2g)
NEW
TIME-SAVING.
TYZAVAN.™
TYZAVAN™ is the only FDA approved,
ready-to-use, shelf stable at room
temperature vancomycin premix.1
Join us at Booth #2041 during the 2025 ASHP Midyear Clinical Meeting & Exhibition
in Las Vegas to learn more about TYZAVAN™ (vancomycin injection, USP).
Important Safety Information for TYZAVANTM (vancomycin injection, USP):
CONTRAINDICATIONS
TYZAVANTM is contraindicated in patients with known hypersensitivity to vancomycin.
WARNINGS & PRECAUTIONS
• Infusion Reactions – Hypotension, including shock and cardiac arrest, wheezing, dyspnea, urticaria or pruritus, muscular and chest pain and “vancomycin
infusion reactions” which manifests as pruritus and erythema face, neck and upper body pruritus and erythema may occur with rapid TYZAVANTM
administration (e.g., over several minutes). The reactions may be more severe in pediatric patients. To reduce the risk of infusion reactions, administer
TYZAVANTM over a period of 60 minutes or greater and also prior to intravenous anesthetic agents.
• Nephrotoxicity – TYZAVANTM can result in acute kidney injury (AKI), including acute renal failure, mainly due to interstitial nephritis or less commonly acute
tubular necrosis. Monitor renal function in all patients.
• Ototoxicity – Ototoxicity may be reversible or permanent in patients receiving vancomycin. It is higher risk in older patients and patients who are
receiving higher doses and manifests as tinnitus, hearing loss, dizziness or vertigo. Serial tests of auditory function may be helpful.
• Severe Dermatologic Reactions – such as toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), drug reaction with eosinophilia and
systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP), and linear IgA bullous dermatosis (LABD) have been reported in
association with the use of vancomycin. Cutaneous signs or symptoms reported include skin rashes, mucosal lesions, and blisters. Discontinue TYZAVANTM
at the first appearance of any signs and symptoms of TEN, SJS, DRESS, AGEP, or LABD.
WARNINGS & PRECAUTIONS Continued at end of column on the next page.